BIM
TAK icon

Baldwin Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

Baldwin Investment Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,824
Closed -$563K – 260
2021
Q1 		$563K Sell
30,824
-2,360
-7% -$42.5K 0.1% 140
2020
Q4 		$604K Sell
33,184
-4,933
-13% -$86.6K 0.12% 130
2020
Q3 		$680K Sell
38,117
-2,450
-6% -$44.6K 0.16% 102
2020
Q2 		$727K Buy
40,567
+1,700
+4% +$30.5K 0.23% 67
2020
Q1 		$590K Sell
38,867
-1,550
-4% -$28.1K 0.2% 69
2019
Q4 		$797K Buy
40,417
+3,490
+9% +$66.8K 0.21% 72
2019
Q3 		$635K Buy
36,927
+1,293
+4% +$22.4K 0.18% 81
2019
Q2 		$631K Buy
35,634
+1,700
+5% +$30.9K 0.18% 84
2019
Q1 		$691K Buy
+33,934
New +$683K 0.21% 77

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Baldwin Investment Management's TAK Position: Q2 2021 in Review

Baldwin Investment Management sold out of Takeda Pharmaceutical (TAK) in Q2 2021, closing a stake of 30,824 shares — an estimated $563K sold.

Baldwin Investment Management first reported a position in TAK in Q1 2019 and held it in 9 quarters. The position peaked at $797K in Q4 2019. 304 funds tracked by Wall St. Rank hold TAK as of Q2 2021.

  • Baldwin Investment Management reported no remaining Takeda Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Baldwin Investment Management sold 30,824 Takeda Pharmaceutical shares in Q2 2021, an estimated $563K.
  • Baldwin Investment Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 9 quarters.
  • Baldwin Investment Management's Takeda Pharmaceutical position peaked at $797K in Q4 2019.
  • 304 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2021.

Based on Baldwin Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.